

Electronic Annex 1: Participating countries and details on the cases reported

Countries	Estimated coverage ^Ω %	Cases enrolled N	Cases treated with Bdq only N (%)	Cases treated with Dlm only N (%)	Cases treated with Bdq and Dlm consecutively or in combination N (%)	Ethical committee clearance not necessary/waived yes/no
Argentina	100	3	3 (100)	0 (0)	0 (0)	yes
Australia	100 [§]	6	6 (100)	0 (0)	0 (0)	yes
Belarus [¶]	80	45	31 (69)	14 (31)	0 (0)	yes
Belgium	60	3	3 (100)	0 (0)	0 (0)	no (obtained)
Brazil	100	34	34 (100)	0 (0)	0 (0)	yes
Bulgaria	100	17	17 (100)	0 (0)	0 (0)	yes
Chile	100	1	0 (0)	0 (0)	1 (100)	yes
China [^]	100 [#]	5	5 (100)	0 (0)	0 (0)	yes
Greece	100	6	4 (67)	0 (0)	2 (33)	yes
India	100 [§]	15	12 (80)	1 (7)	2 (13)	yes
Italy [§]	80	33	26 (79)	6 (18)	1 (3)	no (obtained)
Latvia	100	30	21 (70)	3 (10)	6 (20)	no (obtained)
Lithuania ^{^^}	100	160	100 (62)	52 (33)	8 (5)	yes
Mexico ^{¶¶}	100	7	2 (29)	2 (29)	3 (42)	no (obtained)
Netherlands [¶]	100	6	3 (50)	0 (0)	3 (50)	yes
Niger	100	17	12 (71)	0 (0)	5 (29)	yes
Paraguay	100	1	1 (100)	0 (0)	0 (0)	yes
Peru	80	29	29 (100)	0 (0)	0 (0)	yes
Portugal	100	1	0 (0)	1 (100)	0 (0)	no (obtained)
Russian Federation [¶]	100*	202	195 (97)	2 (1)	5 (2)	no (obtained)
Slovakia	100	1	1 (100)	0 (0)	0 (0)	yes
Spain [§]	100	8	7 (88)	0 (0)	1 (12)	yes
Sudan	100	2	2 (100)	0 (0)	0 (0)	yes
Sweden	100	19	18 (95)	0 (0)	1 (5)	no (obtained)
Switzerland	100 [#]	3	2 (67)	0	1 (33)	no (obtained)
United Kingdom	20	4	4 (100)	0 (0)	0 (0)	yes
TOTAL 26	Range 20%-100%	658	538 (82)	81 (12)	39 (6)	

Legend: Bdq= bedaquiline; Dlm= delamanid

Ω Countries' estimate of the national coverage of the aDSM project on new drugs;

¶ 2 centres;

^ 1 centre;

in the Province/Canton reporting;

§ in the State reporting;

\$ 6 centres;

^^ 5 centres;

¶¶ 3 centres;

*in the 2 Oblasts reporting;